abstract |
Provided are pharmaceutical compositions comprising metformin and a DPP-4 inhibitor and/or a SGLT-2 inhibitor. A preferred DPP-4 inhibitor is linagliptin. A preferred SGLT-2 inhibitor is 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene. The pharmaceutical composition may comprise the following: a)an inner extended release core comprising metformin (particularly metformin hydrochloride) and one or more excipients; b)an optional intermediate seal coating; and c)an outer immediate release coating comprising at least one active pharmaceutical ingredient selected from: a DPP-4 inhibitor, preferably linagliptin, and a SGLT-2 inhibitor, preferably 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, and one or more excipients. The pharmaceutical compositions may be useful in the treatment of metabolic disorders such as diabetes. |